Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia

Experimental Hematology

Volumn 31, Issue 8, 2003, Pages 682-685

  Groneberg, Claudia ^a   Pickartz, Tilman ^a   Binder, Alexander ^a   Ringel, Frauke ^a   Srock, Stefanie ^a   Sieber, Thomas ^a   Schoeler, Dagmar ^a   Schriever, Folke ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; CANCER SURVIVAL; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; T LYMPHOCYTE;

EID: 0041666370     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00109-7     Document Type: Article

References (14)

1. Osorio L.M., Aguilar-Santelises M. Apoptosis in B-chronic lymphocytic leukaemia. Med Oncol. 15:1998;234-240.
2. Krammer P.H. CD95's deadly mission in the immune system. Nature. 407:2000;789.
3. O'Brien S., del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 85:1995;307.
4. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48:1981;198.
5. Sembries S., Pahl H., Stilgenbauer S., Döhner H., Schriever F. Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood. 93:1999;624.
6. Hallek M., Kuhn-Hallek I., Emmerich B. Prognostic factors in chronic lymphocytic leukemia. Leukemia. 11:(suppl 2):1997;S4.
7. Osorio L.M., Aguilar-Santelises M., De Santiago A., Hachiya T., Mellstedt H., Jondal M. Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol. 66:2001;342.
8. Hara T., Tsurumi H., Takemura M., et al. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol. 64:2000;257.
9. + tumor cells in B-chronic lymphocytic leukemia. Blood. 91:1998;4273.
10. Ju S.T., Panka D.J., Cui H., et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995;444.
11. Brunner T., Mogil R.J., LaFace D., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441.
12. Oyaizu N., McCloskey T.W., Than S., Hu R., Kalyanaraman V.S., Pahwa S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. Blood. 84:1994;2622.
13. Klas C., Debatin K.M., Jonker R.R., Krammer P.H. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol. 5:1993;625.
14. O'Flaherty E., Wong W.K., Pettit S.J., Seymour K., Ali S., Kirby J.A. Regulation of T-cell apoptosis: a mixed lymphocyte reaction model. Immunology. 100:2000;289-299.